Compare NXRT & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXRT | OABI |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 582.3M | 696.4M |
| IPO Year | 2014 | 2021 |
| Metric | NXRT | OABI |
|---|---|---|
| Price | $19.46 | $4.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $26.50 | $8.40 |
| AVG Volume (30 Days) | 701.2K | ★ 1.2M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $251,281,000.00 | $18,666,000.00 |
| Revenue This Year | $2.06 | $87.33 |
| Revenue Next Year | $2.37 | $24.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.14 | $1.32 |
| 52 Week High | $32.36 | $5.43 |
| Indicator | NXRT | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 36.16 | 52.33 |
| Support Level | N/A | $1.71 |
| Resistance Level | $24.77 | $5.43 |
| Average True Range (ATR) | 0.81 | 0.32 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 35.53 | 41.67 |
NexPoint Residential Trust Inc is a real estate investment trust company. The trust's objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.